<div id="readability-page-1"><div>Deadline Approaching: Regencell Bioscience Holdings Limited (RGC) Shareholders Who Lost Money Urged To Contact Law Offices of Howard G. Smith Law Offices of Howard G. Smith reminds investors of the upcoming June 23, 2026 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Regencell Bioscience Holdings Limited (“Regencell” or the “Company”) (NASDAQ: RGC) securities between October 28, 2024 and October 31, 2025, inclusive (the “Class Period”). IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN REGENCELL BIOSCIENCE HOLDINGS LIMITED (RGC), CONTACT THE LAW OFFICES OF HOWARD G. SMITH TO PARTICIPATE IN THE ONGOING SECURITIES FRAUD LAWSUIT. Contact the Law Offices of Howard G. Smith to discuss your legal rights by email at howardsmith@howardsmithlaw.com, by telephone at (215) 638-4847 or visit our website at www.howardsmithlaw.com. What Happened? On October 31, 2025, Regencell disclosed that “following recent volatility in the market for [its] Ordinary Shares, the Company received correspondence and a subpoena from the U.S. Department of Justice (‘DOJ’), indicating that the DOJ is conducting an investigation into the trading in [its] Ordinary Shares.” The Company further stated that “[t] he DOJ has requested the production of documents and communications concerning these and other corporate operational, financial and accounting matters” and that the Company “expect[s] to continue to incur significant legal costs and other expenses in connection with responding to the investigation” and “may be required to pay fines, penalties, damages or settlement costs in excess of [its] insurance coverage, if any, related to the investigation.” On this news, Regencell’s stock price fell $3.09, or 18.56%, to close at $13.56 per share on November 3, 2025, thereby injuring investors. What Is The Lawsuit About? The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) Regencell was vulnerable and/or subject to market manipulation; (2) the resulting volatility in the market for the Company’s ordinary shares exposed Regencell’s investors to significant financial risk; (3) all the foregoing subjected Regencell to a heightened risk of regulatory and/or governmental scrutiny and enforcement action, as well as significant legal, monetary, and reputational harm; and (4) as a result, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times. If you purchased or otherwise acquired Regencell securities during the Class Period, you may move the Court no later than June 23, 2026 to ask the Court to appoint you as lead plaintiff if you meet certain legal requirements. Contact Us To Participate or Learn More: If you wish to learn more about this class action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us: Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020, Telephone: (215) 638-4847 Email: howardsmith@howardsmithlaw.com, Visit our website at: www.howardsmithlaw.com. To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. <img src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1tc3RyMyZzdHk9MjAyNjA1MDc0NTA4NjdyMQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" original-src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1tc3RyMyZzdHk9MjAyNjA1MDc0NTA4NjdyMQ"/> Law Offices of Howard G. Smith Howard G. Smith, Esquire 215-638-4847 howardsmith@howardsmithlaw.com www.howardsmithlaw.com View source version on businesswire.com: https://www.businesswire.com/news/home/20260507450867/en/</div></div>

腦再生科技

標普生物技術 3 倍做多 - Direxion

納斯達克生物科技指數 ETF - iShares Nasdaq

標普生物技術 ETF - SPDR

醫療業 ETF - SPDR

紐交所高增長板生物技術指數 ETF - First Trust

生物科技 ETF - VanEck Vectors

動態生物技術與基因組 ETF - Invesco

醫藥突破 ETF - ALPS

呼籲在 2026 年 6 月 23 日截止日期之前遭受損失的 Regencell Bioscience Holdings Limited (RGC) 股東聯繫霍華德·G·史密斯律師事務所，以提交證券欺詐訴訟的首席原告動議。該訴訟源於 Regencell 披露了對其交易行為的司法部調查，這導致股價大幅下跌。2024 年 10 月 28 日至 2025 年 10 月 31 日期間購買股票的投資者可能有資格參與集體訴訟

Deadline Approaching: Regencell Bioscience Holdings Limited (RGC) Shareholders Who Lost Money Urged To Contact Law Offices of Howard G. Smith

MorningStar

截止日期臨近：損失資金的 Regencell Bioscience Holdings Limited（RGC）股東被敦促聯繫 Howard G. Smith 律師事務所